Andrew Hirsch is CEO & President at C4 Therapeutics, Inc. (CCCC). They have made 1 open-market trade across 1 company since 2022, most recently 2026-02-15.
CIK 0001586707
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $84K since 2022, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CCCC | BUY | 2022-04-12 | 2022-04-12 | $8.40 | $84K | -0.4% | -28.2% | +1.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.